Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalized Systemic Therapies in Hereditary Cancer Syndromes

9 Mar 2023

Abstract excerpt

Hereditary cancer syndromes are inherited disorders caused by germline pathogenic variants (PVs) that lead to an increased risk of developing certain types of cancer, frequently at an earlier age than in the rest of the population. The germline PVs promote cancer development, growth and survival, and may represent an ideal target for the personalized treatment of hereditary tumors. PARP inhibitors for the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36980956
DOI: 10.3390/genes14030684

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 20 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized Systemic Therapies in Hereditary Cancer SyndromesPMID 36980956Read ↗

Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects.Semantic proximity Read ↗

Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.Semantic proximity Read ↗

Personalized cancer care.Semantic proximity Read ↗

Novel Cancer Prevention Strategies in Individuals With Hereditary Cancer Syndromes: Focus on BRCA1, BRCA2, and Lynch Syndrome.Semantic proximity Read ↗

Cytotoxic and targeted therapy for hereditary cancersSemantic proximity Read ↗

RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectivesSemantic proximity Read ↗

Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome.Semantic proximity Read ↗

What About the Others? Clinical Management of Gynecologic Cancer Risk in Patients With Moderate-Risk Hereditary Cancer Genes ( ATM , BRIP1 , RAD51C , RAD51D , and PALB2 ).Semantic proximity Read ↗

Biology and Development of DNA-Targeted Drugs, Focusing on Synthetic Lethality, DNA Repair, and Epigenetic Modifications for Cancer: A ReviewSemantic proximity Read ↗

Invited commentary: Are specific inherited mutations important in clinical management of hereditary cancer syndromes?Semantic proximity Read ↗

Personalized medicine: Special treatment.Semantic proximity Read ↗

Update on the Treatment of Medullary Thyroid Carcinoma in Patients with Multiple Endocrine Neoplasia Type 2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.